All In Biotech

Drug Trial Radar · NCT06320431

ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632

A Multicentre, Prospective, Randomized, Open Label, Blinded-endpoint Trial to Optimize the Use of Intravenous Tenecteplase in Participants With Acute Ischemic Stroke (ACT-GLOBAL THROMBOLYSIS (ACT WHEN-001) Within A Multi-faCtorial, mulTi-arm, Multi-staGe, Randomised, gLOBal Adaptive pLatform Trial for Stroke (ACT-GLOBAL) NCT06352632

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 4,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

4,000

Planned (sponsor's estimate)

Start

Sep 26, 2024

Primary completion

Sep 30, 2030

Study completion Dec 31, 2030

Sponsor

Lead sponsor
University of CalgaryAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The George Institute for Global Health, Australia
First posted
Mar 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This domain has a prospective, randomized, controlled, open-label, parallel group with blinded endpoint assessment (PROBE) design. Up to 4,000 patients with presumed acute ischemic stroke (AIS) will be followed for 90 days (or until death, if prior to 90 days). The end of the trial is defined as the date that all participants have completed their Day 90 assessment. This domain aim is to efficiently, reliably, and simultaneously, determine the comparative effectiveness of intravenous thrombolysis (IVT) using standard-dose intravenous tenecteplase (0.25 mg/kg body weight), vs. low-dose intravenous tenecteplase (0.18 mg/kg body weight) in all patients who present to hospital with acute ischemic stroke and are considered for intravenous thrombolysis. In addition, this domain also seeks to study standard-dose intravenous tenecteplase (0.25 mg/kg body weight), vs. low-dose intravenous tenecteplase (0.18 mg/kg body weight) vs. no TNK upfront with rescue IA TNK if necessary (in those eligible for emergency EVT) and no TNK upfront in those who have taken DOACs during the preceding 48 hours. This domain therefore seeks to generate more robust randomized evidence to guide clinicians in their decisions over the balance of risks and treatment with intravenous thrombolysis with tenecteplase wherever such evidence is currently insufficient. This domain will currently evaluate four research questions in relation to the use of IVT with tenecteplase: 1. In patients with recent (48 hours) intake of a standard-dose direct oral anticoagulant (DOAC), how should IVT be used? - Use standard-dose (0.25 mg/kg body weight) or low-dose tenecteplase (0.18 mg/kg) or not at all. 2. In patients planned to be treated with endovascular thrombectomy, how should tenecteplase be used? -Treat with IV tenecteplase (standard- or low-dose) or not at all. 3. In any patient receiving IVT, what is the optimal dose of tenecteplase? - use standard-dose (0.25 mg/kg body weight) or low-dose tenecteplase (0.18 mg/kg). 4. To what extent is the treatment effect of standard- vs. low-dose tenecteplase modified by key patient characteristics, such as diabetes, prior antiplatelet therapy, renal failure, or frailty, old age or having a heavy burden of cerebral small vessel disease on brain imaging.

Conditions

  • Acute Ischemic Stroke AIS
  • Stroke Acute
  • Stroke, Acute, Stroke Ischemic

Interventions

  • TenecteplaseDrug

    Thrombolytic

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. A reduction of functional dependence analyzed across the whole distribution of outcomes assessed on the modified Rankin Scale (mRS),Time frame: From enrollment to the Day 90 assessment - Day 90 outcomes are assessed in a blinded manner

Locations

24 sites in 2 countries. Site status is shown where the registry gives one.

  • The George Institute for Global Health

    Sydney, Barangaroo, Australia · Not yet recruiting

  • Royal Prince Alfred Hospital

    Sydney, New South Wales, Australia · Recruiting

  • Monash University (Box Hill)

    Melbourne, Victoria, Australia · Recruiting

  • University of Alberta

    Edmonton, A, Canada · Recruiting

  • University of Calgary

    Calgary, Alberta, Canada · Recruiting

  • Medicine Hat Regional Hospital

    Medicine Hat, Alberta, Canada · Not yet recruiting

  • Red Deer Regional Hospital

    Red Deer, Alberta, Canada · Not yet recruiting

  • Kelowna Regional Hospital

    Kelowna, British Columbia, Canada · Not yet recruiting

  • Royal Columbian Hospital

    New Westminster, British Columbia, Canada · Not yet recruiting

  • University of British Columbia

    Vancouver, British Columbia, Canada · Recruiting

  • Brandon Regional Hospital

    Brandon, Manitoba, Canada · Not yet recruiting

  • University of Manitoba - Winnipeg Health Science Centre

    Winnipeg, Manitoba, Canada · Recruiting

  • Queen Elizabeth II Health Science Center (Halifax)

    Halifax, Nova Scotia, Canada · Not yet recruiting

  • Health Sciences North Horizon Sante-Nord

    Greater Sudbury, Ontario, Canada · Recruiting

  • McMaster University Hamilton Health Sciences Centre

    Hamilton, Ontario, Canada · Recruiting

  • Kingston General Hospital

    Kingston, Ontario, Canada · Not yet recruiting

  • Lawson Health Research Institute- London

    London, Ontario, Canada · Not yet recruiting

  • Ottawa Hospital Research Institute

    Ottawa, Ontario, Canada · Recruiting

  • St. Michael's Hospital

    Toronto, Ontario, Canada · Recruiting

  • Sunnybrook Health Science Centre

    Toronto, Ontario, Canada · Recruiting

  • Queen Elizabeth Hospital (PEI)

    Charlottetown, Prince Edward Island, Canada · Recruiting

  • Centre Hospitalier de l'Université de Montréal (CHUM)

    Montreal, Quebec, Canada · Not yet recruiting

  • CIUSSS de l'Estrie - CHUS Fleurimont Hôpital (Sherbrooke)

    Sherbrooke, Quebec, Canada · Not yet recruiting

  • Royal University Hospital

    Saskatoon, Saskatchewan, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.